Dr. Elyse Julian, DO
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Years since graduation
- 11
- In the NPI registry since
- 2016
- Medicare patients seen, 2024
- 405
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2016Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
FL license UO5205
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- The Derm Group LLP (32 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 405
- Services billed
- 2,861
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 344 | 67 |
| New patient office or other outpatient visit, 30-44 minutes | 152 | 152 |
| Destruction of precancer skin growth, 1 growth | 149 | 91 |
| Biopsy of related skin growth, first growth | 126 | 101 |
| Biopsy of related skin growth, each additional growth | 95 | 50 |
| Established patient office or other outpatient visit, 20-29 minutes | 92 | 70 |
| Established patient office or other outpatient visit, 30-39 minutes | 60 | 44 |
| Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | 58 | 24 |
| Application of light with debridement to destroy precancer skin growth | 44 | 25 |
| New patient office or other outpatient visit, 45-59 minutes | 28 | 28 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 21 companies reported 178 payments worth $3,696 in total to this clinician.
| Genzyme Corporation | $496 |
|---|---|
| AbbVie Inc. | $496 |
| Organogenesis Inc. | $354 |
| Janssen Biotech, Inc. | $275 |
| Pfizer Inc. | $269 |
| Regeneron Healthcare Solutions, Inc. | $260 |
| UCB, Inc. | $236 |
| Lilly USA, LLC | $215 |
| Food and Beverage | $3,696 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $289,222 in research payments for these studies, mostly to the institutions running them.
- A phase 4, multicenter, open-label, single-arm study to investigate the efficacy of lebrikizumab in adult and adolescent participants with atopic dermatitis with limited body surface area involvement and high itch bur…
Eli Lilly and Company - Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
Eli Lilly and Company · Completed · NCT06588283 - Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne
Sanofi Pasteur Inc. · Recruiting · NCT06316297
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.